首页 | 本学科首页   官方微博 | 高级检索  
     

RCAS1在胰腺癌诊断中的作用
引用本文:杨盈赤,赵玉沛,廖泉,张太平,胡亚,戴梦华. RCAS1在胰腺癌诊断中的作用[J]. 中华外科杂志, 2009, 47(13). DOI: 10.3760/cma.j.issn.0529-5815.2009.13.012
作者姓名:杨盈赤  赵玉沛  廖泉  张太平  胡亚  戴梦华
作者单位:中国医学科学院北京协和医院基本外科,100730
摘    要:目的 评价SiSo细胞表达的受体结合癌抗原(RCAS1)在胰腺癌诊断中的作用.方法 应用酶联免疫吸附分析法检测46例胰腺癌患者、18例慢性胰腺炎患者和20名健康人血清中RCAS1、CA19-9和CA242的含量.用ROC曲线法对检测结果进行分析.应用免疫组织化学染色法对32例胰腺癌、10例慢性胰腺炎以及6例正常胰腺组织切片进行染色,观察RCAS1在胰腺癌和正常胰腺组织中的表达情况.同时对结果进行统计学分析.结果 3种肿瘤标志物的水在胰腺癌组均高于慢性胰腺炎组和正常对照组,且差异均有统计学意义(P<0.01).运用ROC曲线法对3种肿瘤标志物的检测结果进行处理.RCAS1、CA19-9和CA242的曲线下面积分别为0.826、0.804和0.737.分层分析表明,RCAS1和CA19-9在有梗阻性黄疸组高于无梗阻性黄疸组(P<0.01),CA19-9在手术无法切除组高于手术可切除组(P<0.01).胰腺癌组织中RCAS1表达的阳性率为87.5%,慢性胰腺炎组织为40.0%,两组差异有统计学意义(P<0.05).结论 RCAS1在胰腺癌组织中高表达,作为血清肿瘤标志物对胰腺癌的综合诊断能力优于CA19-9和CA242,若同时联合检测CA19-9,则对提高胰腺癌早期诊断和术前可切除性评估准确率有一定的临床价值.

关 键 词:胰腺肿瘤  诊断  肿瘤标志物  ROC曲线

Evaluation of RCAS1 as serum tumor marker for pancreatic cancer
YANG Ying-chi,ZHAO Yu-pei,LIAO Quan,ZHANG Tai-ping,HU Ya,DAI Meng-hua. Evaluation of RCAS1 as serum tumor marker for pancreatic cancer[J]. Chinese Journal of Surgery, 2009, 47(13). DOI: 10.3760/cma.j.issn.0529-5815.2009.13.012
Authors:YANG Ying-chi  ZHAO Yu-pei  LIAO Quan  ZHANG Tai-ping  HU Ya  DAI Meng-hua
Abstract:Objective To evaluate the effect of receptor-binding cancer antigen expressed on SiSO cells(RCASI) as serum tumor marker on the diagnosis of pancreatic cancer. Methods Receiver-operating characteristics(ROC) curve methods were used to assay the serum content of RCAS1 ,CA19-9 and CA242 in 46 patients with pancreatic cancer, 18 patients and 20 normal tissues of chronic pancreatitis detected by enzymelinkod immunosorbent assay (ELISA), and the results were analyzed by statistics methods. The expressions of RCAS1 protein were analyzed by immunohistochemical method in 32 patients with pancreatic cancer, 10 patients with chronic pancreatitis and 6 cases of normal pancreatic specimens. Results The serum levels of RCAS1 ,CA19-9 and CA242 in pancreatic cancer were higher than that in chronic pancreatitis respectively (P < 0.01). The area under curve of RCAS1, CA19-9 and CA242 were 0.826, 0.804 and 0.737 ,respectively. Subgroup analysis indicated that the RCAS1 and CA19-9 levels of pancreatic cancer patients without obstructive jaundice were lower than those for patients with obstructive jaundice (P<0.01). CA19-9 levels of patients with resectable pancreatic cancer were lower than those with unresectable pancreatic cancer(P < 0.01). Immunohistochemistry showed that the expression rates of RCAS1 in pancreatic cancer and chronic pancreatitis were 87.5% and 40.0% ,respectively (P <0. 05). Conclusions In diagnosis of pancreatic cancer,the clinical value of RCAS1 is available. And the combination test of RCAS1 and CA19-9 have clinical value to evaluate if the pancreatic cancer can be resected before operation.
Keywords:Pancreatic neoplasms  Diagnosis  Tumor marker  ROC curve methods
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号